More Articles

Generics versus biosimilars: pricing and usage-enhancing policies Biosimilars/Research | Posted 23/02/2018

In Europe, pricing and demand-side measures for generic medicines are widely implemented and have undergone evaluations [1-4].  However, when it comes to biosimilars, the policies implemented...

China adopts ICH guidelines and collaborates with UK Guidelines | Posted 23/02/2018

As of 1 February 2018, the China Food and Drug Administration (CFDA) will be adopting five safety and regulatory guidelines from the International Council for Harmonisation of Technical Requirement...

MENA region biologicals maker CinnaGen received EU GMP certification Pharma News | Posted 23/02/2018

Iranian biopharmaceutical company, CinnaGen, has been issued a certificate of good manufacturing practice (GMP) compliance by the European Union (EU) at the end of 2017.

Biosimilars of denosumab Biosimilars/General | Posted 23/02/2018

Denosumab is a humanized monoclonal antibody that is an inhibitor of the receptor activator of nuclear factor kappa-B ligand (RANKL), which works by preventing the development of osteoclasts which...

Canada’s generics industry to cut prices by up to 40% Generics/General | Posted 23/02/2018

The pan-Canadian Pharmaceutical Alliance (pCPA) announced on 29 January 2018 that together with participating federal, provincial and territorial public drug plans, and the Canadian Generic Ph...

Launch of biosimilars info for healthcare professionals Reports | Posted 23/02/2018

During the European Commission’s (EC) third workshop on biosimilars, which was held in Brussels, Belgium on 5 May 2017 [1], the EC launched its new information guide on biosimilars for healthcare p...

Persistence with generic imatinib in CML patients Generics/Research | Posted 23/02/2018

A study carried out by researchers from Canada investigated the clinically comparability of brand-name and generic imatinib in patients treated for chronic myeloid leukaemia (CML) [1].

Etanercept switching study investigates non-mandatory transitioning Biosimilars/Research | Posted 23/02/2018

A study carried out by researchers from The Netherlands investigated whether non-mandatory transitioning from originator to biosimilar etanercept improves retention rates [1].